Overview
In the clinical research phase, siRNA and hepatitis B neutralizing antibody therapies have entered phase II clinical trials. The two-drug combination therapy, a global leader in development, aims to achieve a functional cure for hepatitis B.
National Service Hotline
021-33670502
Working hours:
Monday to Friday: 9:00-17:30